Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
1.740
-0.140 (-7.45%)
At close: Nov 4, 2024, 4:00 PM
1.751
+0.011 (0.62%)
After-hours: Nov 4, 2024, 7:46 PM EST
Sangamo Therapeutics Employees
Sangamo Therapeutics had 405 employees as of December 31, 2023. The number of employees decreased by 73 or -15.27% compared to the previous year.
Employees
405
Change (1Y)
-73
Growth (1Y)
-15.27%
Revenue / Employee
$30,314
Profits / Employee
-$616,481
Market Cap
362.30M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Cross Country Healthcare | 13,131 |
ZimVie | 2,600 |
Amylyx Pharmaceuticals | 384 |
Esperion Therapeutics | 240 |
ProQR Therapeutics | 157 |
C4 Therapeutics | 145 |
MaxCyte | 143 |
Theravance Biopharma | 99 |
SGMO News
- 11 hours ago - Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast - Business Wire
- 12 days ago - Sangamo: Fabry Disease Gene Therapy Moves Forward With Positive FDA Regulatory Development - Seeking Alpha
- 13 days ago - Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025 - Business Wire
- 14 days ago - Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. - Seeking Alpha
- 3 months ago - Sangamo Therapeutics, Inc. (SGMO) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results - Business Wire
- 3 months ago - Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases - Business Wire
- 3 months ago - Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast - Business Wire